|
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
RECRUITINGPhase 3Sponsored by Beijing Tiantan Hospital
Actively Recruiting
PhasePhase 3
SponsorBeijing Tiantan Hospital
Started2025-10-09
Est. completion2027-12-30
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07116811
Summary
The purpose of this study is to evaluate the efficacy and safety of steroids treatment compared with placebo in preserving facial nerve function after craniotomy in patients with vestibular schwannoma who have not received preoperative treatment and have good intraoperative facial nerve function.
Eligibility
Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Age between 18 and 70 years 2. Diagnosed with untreated unilateral vestibular schwannoma 3. No facial palsy before surgery (House-Brackmann grade I) 4. Intraoperative neurophysiological monitoring confirms good facial nerve function preservation, defined as: a)Post-tumor resection, evoked compound muscle action potential amplitude \>420 μV under 0.05 mA stimulation;and b)The amplitude is \>60% of baseline value measured before dural opening 5. Signed informed consent Exclusion Criteria: 1. Contraindications for craniotomy 2. Patients requiring corticosteroids during the perioperative period, or with known corticosteroid contraindications 3. Patients or first-degree relatives with a confirmed diagnosis of neurofibromatosis type 2 (NF2) 4. Karnofsky Performance Status (KPS) score \<90 before disease onset 5. Pregnant or planning to become pregnant during the study period 6. Participation in other interventional clinical trials 7. Judged unsuitable by the investigators
Conditions3
CancerFacial Nerve ParalysisVestibular Schwannoma
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorBeijing Tiantan Hospital
Started2025-10-09
Est. completion2027-12-30
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07116811